[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336551-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336551-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","pan-cancer-mapping-of-single-cd8-t-cell-profiles-reveals-a-tcf1cxcr6-axis-regulating-cd28-co-stimulation-and-anti-tumor-immunity","Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity","","CD8+ T cells must persist and function across diverse tumor microenvironments to drive anti-tumor effects. The study applies a generalizable matrix factorization approach to a large scRNA-seq compendium (33,161 CD8+ T cells from 132 patients with seven cancers) to recover shared and context-specific gene programs. Meta-single-cell analyses identify a pan-cancer T cell dysfunction program linked to clinical non-response to checkpoint blockade in melanoma and highlight CXCR6 as a marker of chronically activated T cells. Mechanistically, TCF1 represses CXCR6, while AP-1 transactivates it; CXCR6 supports survival and CD28 signaling, and CD8-specific Cxcr6 deletion impairs tumor control.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/pan-cancer-mapping-of-single-cd8-t-cell-profiles-reveals-a-tcf1cxcr6-axis-regulating-cd28-co-stimulation-and-anti-tumor-immunity/336551/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/pan-cancer-mapping-of-single-cd8-t-cell-profiles-reveals-a-tcf1cxcr6-axis-regulating-cd28-co-stimulation-and-anti-tumor-immunity/336551.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What computational strategy is used to study CD8+ T cells across cancers?","Question",{"text":63,"@type":64},"A generalizable matrix factorization algorithm is used to extract shared and context-specific expression programs from diverse datasets using a large scRNA-seq compendium.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does TCF1 relate to CXCR6 expression in chronically activated CD8+ T cells?",{"text":68,"@type":64},"CXCR6 expression is transactivated by AP-1 and repressed by TCF1, defining a regulatory TCF1:CXCR6 axis.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the impact of deleting Cxcr6 in CD8+ T cells in mouse models?",{"text":72,"@type":64},"Cxcr6 deletion increases apoptosis of PD1+TIM3+ cells, dampens CD28 signaling, and compromises tumor growth control.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336551,1790169185,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nPan-cancer mapping of single CD8+ T cell proﬁles reveals a TCF1:CXCR6 axis regulating CD28 costimulation and anti-tumor immunity  \nAuthors  \nKatherine Tooley, Livnat Jerby,  \nGiulia Escobar, ..., Orit Rozenblatt-Rosen, Aviv Regev, Ana C. Anderson  \nCorrespondence  \n[ljerby@stanford.edu](ljerby@stanford.edu) (L.J.),  \n[regev.aviv@gene.com](regev.aviv@gene.com) (A.R.),  \n[acanderson@bwh.harvard.edu](acanderson@bwh.harvard.edu) (A.C.A.)  \nIn brief  \nTooley et al. develop a computational method to identify pan-cancer CD8+ T cell gene programs and uncover a regulatory axis wherein TCF1 represses CXCR6 expression. They show CXCR6 expression is necessary for tumor control and promotes the survival of chronically activated anti-tumor T cells in part by promoting CD28 signaling.  \nd Generalizable matrix decomposition framework identiﬁespan-cancer CD8+ T cell programs  \nd CXCR6 is a pan-cancer marker of chronically activated CD8+ T cells  \nd CXCR6 expression is driven by AP-1 and repressed by TCF1  \nd CXCR6 promotes CD8+ T cell survival and tumor control in part via promotion of CD28  \nTooley et al., 2024, Cell Reports Medicine 5, 101640  \nJuly 16, 2024 ª 2024 The Authors. Published by Elsevier Inc.  \n[https://doi.org/10.1016/j.xcrm.2024.101640](https://doi.org/10.1016/j.xcrm.2024.101640)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nPan-cancer mapping of single CD8+ T cell proﬁles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity  \nKatherine Tooley,1,2,8,10 Livnat Jerby,3,4,5,10,* Giulia Escobar,1,8 S. Harsha Krovi,1,8 Davide Mangani,1,8  \nGitanjali Dandekar,1,8 Hanning Cheng,1,8 Asaf Madi,6 Ella Goldschmidt,6 Conner Lambden,1,8 Rajesh K. Krishnan,1,8 Orit Rozenblatt-Rosen,5,9 Aviv Regev,5,7,9,11,* and Ana C. Anderson1,8,11,12,*  \n1The Gene Lay Institute of Immunology and Inﬂammation of Brigham and Women’s Hospital, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA  \n2Division of Medical Sciences, Harvard Medical School, Boston, MA, USA  \n3Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA  \n4Chan Zuckerberg Biohub, San Francisco, CA 94158, USA  \n5Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA  \n6Department of Pathology, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel  \n7Howard Hughes Medical Institute and Koch Institute of Integrative Cancer Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA  \n8Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA  \n9Present address: Genentech, 1 DNA Way, South San Francisco, CA, USA  \n10These authors contributed equally  \n11These authors contributed equally  \n12Lead contact  \n*Correspondence: [ljerby@stanford.edu](ljerby@stanford.edu) (L.J.), [regev.aviv@gene.com](regev.aviv@gene.com) (A.R.), [acanderson@bwh.harvard.edu](acanderson@bwh.harvard.edu) (A.C.A.) [https://doi.org/10.1016/j.xcrm.2024.101640](https://doi.org/10.1016/j.xcrm.2024.101640)  \nSUMMARY  \nCD8+ T cells must persist and function in diverse tumor microenvironments to exert their effects. Thus, understanding common underlying expression programs could better inform the next generation of immunotherapies. We apply a generalizable matrix factorization algorithm that recovers both shared and contextspeciﬁc expression programs from diverse datasets to a single-cell RNA sequencing (scRNA-seq) compendium of 33,161 CD8+ T cells from 132 patients with seven human cancers. Our meta-single-cell analyses uncover a pan-cancer T cell dysfunction program that predicts clinical non-response to checkpoint blockade in melanoma and highlights CXCR6 as a pan-cancer marker of chronically activated T cells. Cxcr6 is transactivated by AP-1 and repressed by TCF1 . Using mouse models, we show that Cxcr6 deletion in CD8+ T cells increases apoptosis of PD1+TIM3+ cells, dampens CD28 signaling, and compromises tumor growth con","cbCaicwVch8hEJTF","https://ap.wps.com/l/cbCaicwVch8hEJTF","pdf",5715227,28,"English","# Summary\n# Methods and computational framework\n## Pan-cancer CD8+ T cell gene programs\n# Key findings\n## CXCR6 as a marker of chronic activation\n## TCF1 repression and AP-1 transactivation\n# Functional validation\n## CD8-specific Cxcr6 deletion effects","[{\"question\":\"What computational strategy is used to study CD8+ T cells across cancers?\",\"answer\":\"A generalizable matrix factorization algorithm is used to extract shared and context-specific expression programs from diverse datasets using a large scRNA-seq compendium.\"},{\"question\":\"How does TCF1 relate to CXCR6 expression in chronically activated CD8+ T cells?\",\"answer\":\"CXCR6 expression is transactivated by AP-1 and repressed by TCF1, defining a regulatory TCF1:CXCR6 axis.\"},{\"question\":\"What is the impact of deleting Cxcr6 in CD8+ T cells in mouse models?\",\"answer\":\"Cxcr6 deletion increases apoptosis of PD1+TIM3+ cells, dampens CD28 signaling, and compromises tumor growth control.\"}]","Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity | PDF",1790015587,71,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c05c3457289d774a3d3d705d69347b84.webp",983,1276,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0ffa1a64dcbefed2ea5a5d556c19d22.webp",982,1275,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6451344b0d9cfd3891c5d13a1e6490fd.webp",981,1273,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a0f7f4063c51547372530be7dacaf2f.webp",980,1272]